natgillin/translations-raw huggingface dataset:
Changes in the way glutamate transmits signals within the brain have been linked to the memory loss seen in Alzheimer's disease, and over-activity of the NMDA receptors can result in cell damage or death. 
Spremembe načina, kako glutamat prenaša signale v možganih, se povezujejo z izgubo spomina, kakršna pri Alzheimerjevi bolezni, prekomerna aktivnost receptorjev
Acetylcholine levels are lower in people suffering from dementia in Alzheimer's disease. 
Pri osebah z Alzheimerjevo boleznijo, ki imajo demenco, so ravni acetilholina nižje.
It is authorised to treat patients with moderate to severe forms of Alzheimer's disease. 
Učinkovina je odobrena za uporabo pri zdravljenju bolnikov z zmerno do hudo obliko Alzheimerjeve bolezni.
How is Acrescent expected to work? 
Kako naj bi zdravilo Acrescent delovalo?
By blocking NMDA receptors, memantine helps to reduce the symptoms of Alzheimer's disease. 
Memantin zavira receptorje NMDA ter tako pomaga lajšati simptome Alzheimerjeve bolezni.
What is Acrescent? 
Kaj je zdravilo Acrescent?
This summary was last updated in September 2015. 
Povzetek je bil nazadnje posodobljen septembra 2015.
This will help protect them against the disease. 
To bo živalim pomagalo pri zaščiti pred boleznijo.
The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Zulvac SBV's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) pri agenciji je zaključil, da so koristi zdravila Zulvac CBV večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The full EPAR for Zulvac SBV can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila Zulvac SBV je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
The European Commission granted a marketing authorisation valid throughout the EU for Zulvac SBV on 6 February 2015. 
Evropska komisija je dovoljenje za promet z zdravilom Zulvac SBV, veljavno po vsej Evropski uniji, izdala 6. februarja 2015.
This is a summary of the European public assessment report (EPAR) for Zulvac SBV. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Zulvac SBV.
The animals were vaccinated according to the vaccination schedule and were then exposed to the Schmallenberg virus. 
Živali so cepili v skladu s shemo cepljenja in jih nato izpostavili virusu Schmallenberg.
Schmallenberg virus vaccine (inactivated) 
cepivo proti virusu Schmallenberg (inaktivirano)
The effectiveness of Zulvac SBV has been investigated in laboratory studies in cattle and sheep. 
Učinkovitost cepiva Zulvac SBV so proučevali v laboratorijskih študijah na govedu in ovcah.
When it is given to cattle or sheep, the animals' immune system recognises the virus as foreign and makes antibodies against it. 
Ko govedo ali ovce prejmejo cepivo, imunski sistem živali prepozna virus kot „tujek“ in začne proti njemu tvoriti protitelesa.
The withdrawal period for meat from cattle and sheep treated with Zulvac SBV is ‘zero' days, which means there is no mandatory waiting time. 
Karenca za meso goveda in ovac, zdravljenih z zdravilom Zulvac SBV, je nič dni, kar pomeni, da ni obvezne čakalne dobe.
Schmallenberg virus is transmitted by midges and causes stillbirths and birth defects in cattle and sheep. 
Virus Schmallenberg prenašajo trzače in povzroča mrtvorojene mladiče ter okvare ploda pri govedu in ovcah.
In the future if the animals are exposed to Schmallenberg virus, the immune system will be able to produce antibodies more quickly. 
Ob ponovni izpostavitvi živali virusu Schmallenberg v prihodnosti bo imunski sistem tako hitreje tvoril protitelesa.
In pregnant ewes vaccination reduced viraemia and infection of the embryo. 
Pri brejih ovcah se je s cepljenjem zmanjšala viremija in okužba zarodka.
Zulvac SBV contains Schmallenberg virus that has been inactivated so that it cannot cause disease. 
Cepivo Zulvac SBV vsebuje virus Schmallenberg, ki je bil inaktiviran in zato ne more povzročiti bolezni.
Zulvac SBV is available as a suspension for injection and can only be obtained with a prescription. 
Zdravilo Zulvac SBV je na voljo v obliki suspenzije za injiciranje in se izdaja le na recept.
Zulvac SBV is a veterinary vaccine used to protect cattle and sheep from 3.5 months of age against Schmallenberg virus by reducing viraemia (presence of virus in the blood). 
Zulvac SBV je zdravilo za uporabo v veterinarski medicini in se uporablja za zaščito goveda in ovac, starejših od treh mesecev in pol, pred virusom Schmallenberg, saj deluje tako, da zmanjša viremijo (prisotnost virusa v krvi).
Other information about Zulvac SBV: 
Druge informacije o zdravilu Zulvac SBV:
Zulvac SBV contains the active substance inactivated (killed) Schmallenberg virus strain BH80/11-4. 
Zdravilo Zulvac SBV vsebuje kot zdravilno učinkovino inaktivirani (uničeni) sev virusa Schmallenberg BH80/11-4.
Zulvac SBV is a vaccine. 
Zdravilo Zulvac SBV je cepivo.
For female sheep vaccination should be at least two weeks before breeding to reduce viraemia (virus in the blood) and infection of the embryo during the first trimester of pregnancy. 
Cepljenje ovčjih samic je treba zaključiti vsaj dva tedna pred parjenjem za zmanjšanje viremije (virusa v krvi) in okužbe zarodka v prvem trimesečju brejosti.
In sheep protection starts three weeks after vaccination and lasts six months. 
Zaščita pri ovcah se razvije tri tedne po cepljenju in traja šest mesecev.
What is Zulvac SBV and what is it used for? 
Kaj je zdravilo Zulvac SBV in za kaj se uporablja?
In cattle protection starts two weeks after vaccination and lasts 12 months. 
Zaščita pri govedu se razvije dva tedna po cepljenju in traja 12 mesecev.
For more information about treatment with Zulvac SBV, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist. 
Za več informacij o zdravljenju z zdravilom Zulvac SBV naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
What benefits of Zulvac SBV have been shown in studies? 
Kakšne koristi je zdravilo Zulvac SBV izkazalo v študijah?
What are the risks associated with Zulvac SBV? 
Kakšna tveganja so povezana z zdravilom Zulvac SBV?
For booster vaccination in cattle two injections of 2 ml should be given three weeks apart every 12 months. 
Za poživitveno cepljenje goveda je treba injicirati dva odmerka po 2 ml v razmiku treh tednov vsakih 12 mesecev.
For practical information about using Zulvac SBV, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist. 
Za praktične informacije o uporabi zdravila Zulvac SBV naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
For booster vaccination in non-breeding sheep a single injection of 1 ml should be given every six months whilst in female breeding sheep a single injection of 1 ml should be given at least two weeks before breeding. 
Za poživitveno cepljenje neplemenskih ovac je treba injicirati en odmerek po 1 ml vsakih šest mesecev, medtem ko je treba pri plemenskih ovčjih samicah enkratni odmerek po 1 ml injicirati vsaj dva tedna pred parjenjem.
The vaccine is given to cattle as two injections of 2 ml into the neck muscle three weeks apart and to sheep as a single injection of 1 ml under the skin behind the elbow. 
Cepivo se govedu injicira v dveh odmerkih po 2 ml v vratno mišico v razmiku treh tednov, ovcam pa se injicira v enem odmerku po 1 ml v podkožje za komolčnim sklepom.
The main measure of effectiveness was absence of viraemia following exposure to the virus.The studies showed that Zulvac SBV protects cattle two weeks and sheep three weeks after vaccination. 
Študije so pokazale, da cepivo Zulvac SBV zaščiti govedo dva tedna in ovce tri tedne po cepljenju.
In sheep more than one in ten animals may have an increase in body temperature of up to 1.5 °C during the 24 hours after vaccination. 
Pri ovcah se lahko pri več kot eni živali od desetih v 24 urah po cepljenju pojavi povišanje telesne temperature za največ 1,5 °C.
Why is Zulvac SBV approved? 
Zakaj je bilo zdravilo Zulvac SBV odobreno?
More than one in ten animals may show swellings or lumps of up to 8 cm in diameter under the skin at the injection site, which may last for at least 97 days as granules less than 0.5 cm in diameter. 
Pri več kot eni živali od desetih se lahko na mestu injiciranja v podkožju pojavijo otekline ali zatrdline, premera do največ 8 cm, ki lahko v obliki granulomov, premera manj kot 0,5 cm, trajajo najmanj 97 dni.
More than one in ten animals may show swellings or lumps of up to 8 cm in diameter under the skin at the injection site, and swellings less than 2 cm in diameter may last for at least 47 days. 
Pri več kot eni živali od desetih se lahko na mestu injiciranja v podkožju pojavijo otekline ali zatrdline, premera do največ 8 cm, otekline, premera manj kot 2 cm, pa lahko trajajo najmanj 47 dni.
In pregnant ewes more than one in ten animals may have an increase in body temperature of up to 0.8 °C during 4 hours after vaccination. 
Pri brejih ovcah se lahko pri več kot eni od desetih živali v 4 urah po cepljenju pojavi povišanje telesne temperature do največ 0,8 °C.
In cattle, an increase in body temperature of up to 1.5°C during the 48 hours after vaccination and the appearance of small lumps of up to 0.7 cm in diameter at the vaccination site that resolve within 10 days are very common (seen in more than 1 animal in 10). 
Pri govedu sta zelo pogosta (opažena pri več kot eni živali od desetih) povišanje telesne temperature do največ 1,5 °C v 48 urah po cepljenju in pojav manjših zatrdlin, premera do največ 0,7 cm, na mestu cepljenja, ki izginejo v desetih dneh.
How is Zulvac SBV used? 
Kako se zdravilo Zulvac SBV uporablja?
How does Zulvac SBV work? 
Kako zdravilo Zulvac SBV deluje?
It is not intended to provide practical advice on how to use Zulvac SBV. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
27 January 2011 
27. januar 2011
The European Commission issued a decision on 27 January 2011. 
Evropska komisija je odločbo izdala dne 27. januarja 2011.
They are available in Austria, Belgium, Cyprus, the Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Luxembourg, the Netherlands, Poland, Portugal, Slovakia, Spain, Sweden and the United Kingdom. 
Zdravila so na voljo v naslednjih državah: Avstrija, Belgija, Ciper, Češka, Danska, Finska, Francija, Nemčija, Grčija, Madžarska, Islandija, Irska, Italija, Luksemburg, Nizozemska, Poljska, Portugalska, Slovaška, Španija, Švedska in Združeno kraljestvo.
Indications restricted following review procedure under Article 31 of Directive 2001/83/EC as amended 
Omejitev indikacij po postopku pregleda v skladu s členom 31 Direktive 2001/83/ES, kakor je bila spremenjena
After re-examination, the Committee confirmed these recommendations on 18 November 2010. 
Po ponovnem pregledu je Odbor dne 18. novembra 2010 ta priporočila potrdil.
Why was modafinil reviewed? 
Zakaj je bil modafinil pregledan?
Questions and answers on the review of medicines containing modafinil 
Vprašanja in odgovori v zvezi s pregledom zdravil, ki vsebujejo modafinil
The Committee recommended that these indications be removed from the product information. 
Odbor je priporočil, da se te indikacije izbrišejo iz informacij o zdravilih.
A group of experts on clinical neurosciences was also convened to provide advice. 
Sklicana je bila tudi skupina strokovnjakov za klinično nevrološko znanost, da bi podala nasvete.
However, the data from the trials in other disorders did not provide strong evidence to support the use of the product. 
Vendar pa podatki iz preskušanj pri drugih motnjah niso zagotovili močnih dokazov v podporo uporabi tega zdravila.
The European Medicines Agency has completed a review of the safety and effectiveness of modafinil. 
Evropska agencija za zdravila je končala pregled varnosti in učinkovitosti modafinila.
What is modafinil? 
Kaj je modafinil?
The CHMP confirmed the above conclusions after re-examining its opinion. 
CHMP je po ponovnem pregledu mnenja potrdil navedene zaključke.
They are available under the following invented names: Modasomil, Modiodal, Provigil and Vigil, and as generic medicines. 
Na voljo so pod naslednjimi izmišljenimi imeni: Modasomil, Modiodal, Provigil in Vigil ter kot generična zdravila.
Excessive sleepiness can also happen with no known causes (idiopathic hypersomnia). 
Čezmerna zaspanost lahko nastopi tudi brez znanih razlogov (idiopatska hipersomnija).
The exact way modafinil works is not fully understood, but it most likely interacts with some chemicals in the brain called neurotransmitters such as dopamine and norepinephrine. 
Natančen način delovanja modafinila še ni povsem znan, vendar najverjetneje medsebojno deluje z nekaterimi kemičnimi snovmi v možganih, imenovanimi živčni prenašalci, kot sta dopamin in norepinefrin.
Because the Committee noted in its review that modafinil has often been used for conditions for which it is not indicated, the companies have also been asked to carry out further studies, including a ‘drug utilisation study' to look at why family doctors prescribe the medicines. 
Ker je Odbor med pregledom opazil, da se modafinil pogosto uporablja za zdravljenje stanj, za katera ni indiciran, je družbe pozval, naj izvedejo dodatne študije, vključno s „študijo o uporabi zdravila“, in ugotovijo, zakaj družinski zdravniki predpisujejo ta zdravila.
Modafinil is used to promote wakefulness (help people stay awake). 
Modafinil se uporablja za spodbujanje budnosti (ljudem pomaga, da ostanejo budni).
Medicines containing modafinil were first marketed in Europe in 1992. 
Zdravila, ki vsebujejo modafinil, so na evropskem trgu od leta 1992.
Once the PhVWP had received and started its assessment of the data, the working party had further concerns about the medicines, and consequently, on 14 May 2009, the UK medicines regulatory agency asked the CHMP to carry out a full assessment of the benefit-risk balance of modafinilcontaining medicines, and to issue an opinion on whether their marketing authorisations should be maintained, varied, suspended or withdrawn across the European Union. 
Po prejemu in začetku ocenjevanja podatkov je delovna skupina za farmakovigilanco ponovno izrazila zadržke o zdravilu in posledično je britanska regulativna agencija za zdravila dne 14. maja 2009 CHMP zaprosila, naj izvede celotno oceno razmerja med koristmi in tveganji za zdravila, ki vsebujejo modafinil, ter izda mnenje, ali je treba dovoljenja za promet s temi zdravili v Evropski uniji ohraniti, spremeniti, začasno umakniti ali ukiniti.
These include informing healthcare professional of the changes to the product information triggered by this latest review, and putting in place studies looking at the cardiovascular and skin safety of modafinil. 
Ti vključujejo obveščanje zdravstvenega osebja o spremembah informacij o zdravilu, ki so nastale po zadnjem pregledu, in zasnovo študij, s katerimi bi preučili srčno-žilno in kožno varnost modafinila.
In addition, data on the misuse of modafinil by university students, currently being collected, will be analysed once available. 
Analizirani bodo tudi podatki o zlorabi modafinila med univerzitetnimi študenti, ki se trenutno še zbirajo in še niso na voljo.
• Doctors should also be aware of the safety profile of modafinil-containing medicines, and they should monitor their patients appropriately. 
• Zdravniki morajo biti pozorni tudi na varnostni profil zdravil, ki vsebujejo modafinil, in ustrezno spremljati bolnike.
Looking at the safety data, the Committee noted that modafinil is strongly linked to a risk of serious, life-threatening skin reactions, and this risk appears higher in children. 
Ob pregledu varnostnih podatkov je Odbor menil, da je modafinil močno povezan s tveganjem resnih, smrtno nevarnih kožnih reakcij in zdi se, da je to tveganje večje pri otrocih.
In addition the Committee also recommended that modafinil-containing medicines not be used in patients with uncontrolled hypertension or irregular heart beat. 
Odbor je tudi priporočil, da se zdravila, ki vsebujejo modafinil, ne uporabljajo pri bolnikih z nenadzorovano hipertenzijo ali nerednim srčnim utripom.
• There is no need for patients to stop treatment with modafinil immediately, but patients who wish to stop can do so at any time. 
• Takojšnje prenehanje zdravljenja z modafinilom ni potrebno; če pa želijo, lahko bolniki zdravljenje kadar koli prekinejo.
This led to an update of the product information for modafinil-containing medicines across Europe to strengthen the warnings about these risks. 
Posledično so po vsej Evropi posodobili informacije o zdravilih za zdravila, ki vsebujejo modafinil, da bi okrepili opozorila o teh tveganjih.
The CHMP also recommended further changes to the product information to ensure that the medicines are used appropriately, and asked the manufacturers to put in place risk minimisation measures. 
CHMP je priporočil tudi dodatne spremembe informacij o zdravilu za zagotovitev pravilne uporabe zdravila in izdelovalce zaprosil, da vzpostavijo ukrepe za zmanjševanje tveganja.
• Doctors prescribing modafinil-containing medicines should keep in mind the change in the indication: modafinil is only indicated to treat narcolepsy. 
• Zdravniki, ki predpisujejo zdravila, ki vsebujejo modafinil, ne smejo pozabiti na spremembe indikacij: modafinil je indiciran le za zdravljenje narkolepsije.
Modafinil-containing medicines are used in patients who suffer from excessive sleepiness. 
Zdravila, ki vsebujejo modafinil, se uporabljajo pri bolnikih, ki imajo težave s pretirano zaspanostjo.
Looking at the data from the clinical trials, the Committee noted that the effectiveness of modafinil in narcoleptic patients had been shown. 
Ob pregledu podatkov iz kliničnih preskušanj je Odbor ugotovil, da je bila učinkovitost modafinila pri bolnikih z narkolepsijo dokazana.
The Committee also noted the increased risk of serious life-threatening skin reactions with modafinil in children and advised against its use in children. 
Odbor je izpostavil tudi povečano tveganje resnih, smrtno nevarnih kožnih reakcij pri uporabi modafinila pri otrocih in odsvetoval uporabo pri otrocih.
Excessive sleepiness can be caused by narcolepsy, a disease that causes the person to fall asleep during the day, or it can be due to disturbed night-time sleeping patterns leading to daytime sleepiness. 
Čezmerno zaspanost lahko povzroča narkolepsija, bolezen, zaradi katere posameznik podnevi zaspi, ali pa je posledica motenih vzorcev nočnega spanja, kar povzroča zaspanost podnevi.
Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the benefits of modafinil-containing medicines continue to outweigh their risks only in the treatment of narcolepsy. 
Na podlagi ocene trenutno razpoložljivih podatkov in znanstvene razprave v Odboru je CHMP zaključil, da koristi zdravil, ki vsebujejo modafinil, še vedno odtehtajo z njimi povezana tveganja le pri zdravljenju narkolepsije.
• Modafinil should no longer be used to treat: Obstructive sleep apnoea; Shift work sleep disorder; Idiopathic hypersomnia. 
• Modafinil se ne sme več uporabljati za zdravljenje: obstruktivne apneje med spanjem, motnje spanja zaradi izmenskega dela, idiopatske hipersomnije.
The Committee also noted a link between modafinil and psychiatric adverse reactions, such as suicidal thoughts, depression, psychotic episodes, and between modafinil and cardiovascular adverse reactions, such as hypertension (high blood pressure) and irregular heart beat. 
Odbor je izpostavil tudi povezavo med modafinilom in neželenimi psihiatričnimi učinki, kot so samomorilne misli, depresija, psihotične epizode, ter med modafinilom in srčno-žilnimi neželenimi učinki, kot sta hipertenzija (visok krvni tlak) in neredni srčni utrip.
The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of modafinil-containing medicines continue to outweigh their risks but that their use should be restricted to the treatment of narcolepsy. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da koristi zdravil, ki vsebujejo modafinil, še vedno odtehtajo z njimi povezana tveganja, vendar je treba njihovo uporabo omejiti samo na zdravljenje narkolepsije.
The Committee looked at all the data from the clinical trials of modafinil in narcolepsy, obstructive sleep apnoea, shift-work sleep disorder and idiopathic hypersomnia, and at articles from the published literature. 
Odbor je preučil vse podatke iz kliničnih preskušanj modafinila pri narkolepsiji, obstruktivni apneji med spanjem, motnji spanja zaradi izmenskega dela in idiopatski hipersomniji ter članke iz objavljene literature.
• Patients who are receiving modafinil-containing medicines should contact their doctors at a convenient time to check that they should continue receiving it. 
• Bolniki, ki prejemajo zdravila, ki vsebujejo modafinil, naj se v ustreznem času oglasijo pri zdravniku in preverijo, ali lahko nadaljujejo zdravljenje s tem zdravilom.
This can be seen in people who work a shift-pattern or in those who suffer from obstructive sleep apnoea (a condition in which pauses in breathing occur repeatedly during the night, disturbing sleep). 
To je mogoče opaziti pri ljudeh, ki delajo v izmenah, in pri posameznikih z obstruktivno apnejo med spanjem (bolezen, pri kateri se ponoči med spanjem neprestano ponavljajo premori pri dihanju, ki motijo spanje).
For obstructive sleep apnoea (including in patients with excessive sleepiness despite correctly using a Continuous Positive Airway Pressure machine), shift-work sleep disorder and idiopathic hypersomnia, the CHMP concluded that the data on the effectiveness were not sufficient to outweigh the risks, and that therefore the benefit-risk balance was negative. 
CHMP je menil, da podatki o učinkovitosti pri obstruktivni apneji med spanjem (vključno z bolniki, ki trpijo za čezmerno zaspanostjo kljub pravilni uporabi aparata za stalni pozitivni tlak v dihalnih poteh), motnji spanja zaradi izmenskega dela in idiopatski hipersomniji niso zadostni, da bi odtehtali tveganja, zato je bilo razmerje med koristmi in tveganji negativno.
The CHMP also reviewed all the side effects reported with modafinil-containing medicines. 
CHMP je pregledal tudi vse neželene učinke, o katerih so poročali pri zdravilih, ki vsebujejo modafinil.
The CHMP has also asked the companies that make modafinil-containing medicines to put in place measures to minimise the risks. 
CHMP je družbe, ki izdelujejo zdravila, ki vsebujejo modafinil, tudi pozval, da vzpostavijo ukrepe za zmanjševanje tveganja.
The PhVWP also asked the companies that make modafinil-containing medicines to provide all information they had to assess if further measures were needed. 
Delovna skupina za farmakovigilanco je družbe, ki izdelujejo zdravila, ki vsebujejo modafinil, zaprosila tudi, da predložijo vse razpoložljive informacije za oceno, ali so potrebni dodatni ukrepi.
In 2007, the CHMP's Pharmacovigilance Working Party (PhVWP) reviewed the safety of modafinilcontaining medicines because of concerns that the medicines were associated with serious psychiatric disorders (suicidal thoughts, mania and symptoms of psychosis such as delusion) and with skin reactions, including severe reactions such as Stevens-Johnson syndrome, a life-threatening type of allergic reaction affecting the skin and mucous membranes. 
(samomorilne misli, manija in simptomi psihoze, kot so blodnje) in kožnimi reakcijami, vključno z resnimi reakcijami, kot je Stevens-Johnsonov sindrom, smrtno nevarna vrsta alergijske reakcije, ki vpliva na kožo in sluznico.
This plan should address the following: 
Plan mora vsebovati:
Training for the patients will be via a healthcare professional. 
Izobraževanje bolnikov bo potekalo preko zdravstvenih delavcev.